10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-GPR44 / PTGDR2 / CD294 Reference Antibody (KHK patent anti-CRTH2)

Recombinant Antibody
Catalog # APR10924

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q9Y5Y4
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	43268


Additional Information

Target/Specificity	GPR44 / PTGDR2 / CD294
Endotoxin Conjugation	Unconjugated
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.


Protein Information

Name	PTGDR2
Synonyms	CRTH2, DL1R, GPR44
Function	Receptor for prostaglandin D2 (PGD2). Coupled to the G(i)- protein. Receptor activation may result in pertussis toxin-sensitive decreases in cAMP levels and Ca(2+) mobilization. PI3K signaling is also implicated in mediating PTGDR2 effects. PGD2 induced receptor internalization. CRTH2 internalization can be regulated by diverse kinases such as, PKC, PKA, GRK2, GPRK5/GRK5 and GRK6. Receptor activation is responsible, at least in part, in immune regulation and allergic/inflammation responses.
Cellular Location	Cell membrane; Multi-pass membrane protein. Note=Internalized receptors colocalized with RAB11A.
Tissue Location	Widespread expression. High expression in stomach, small intestine, heart and thymus. Intermediate expression in colon, spinal cord and peripheral blood and low expression in brain, skeletal muscle and spleen. Expressed also on Th2- and Tc2- type cells, eosinophils and basophils.

Images



Anti-GPR44 / PTGDR2 / CD294 Reference Antibody (KHK patent anti-CRTH2) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti-GPR44 / PTGDR2 / CD294 Reference Antibody (KHK patent anti-CRTH2) is more than 95%, determined by SEC-HPLC.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.